Program
boserolimab
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms, led by Merck.
Furthest: phase 2, since Nov 14, 20195 company-led studies, 1 open or runningNext primary completion: Feb 13, 2032 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 51 open or running | phase 2since Nov 14, 2019 | Jan 4, 2018 | Feb 13, 2032phase 2 · NCT04165070 |
Also a collaborator on its studies: Daiichi Sankyo.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 4, 2018First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03396445 · 182 enrolled · United States, Chile, Israel and more
- Nov 14, 20192 phase 2 studies in Carcinoma, Non-Small-Cell LungNCT04165096, NCT04165070
- Jun 9, 2021Phase 2 study in Small Cell Lung CarcinomaNCT04924101 · 122 enrolled · United States, Austria, Canada and more
- Feb 11, 2025Phase 2 study in Triple Negative Breast NeoplasmsNCT06829199 · United States, Taiwan
Ahead
- Feb 13, 2032Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04165070
TargetBeta
CD27 →read by rule
“A humanized agonistic monoclonal antibody targeting the cell surface antigen CD27, ”NCIt, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06829199Triple Negative Breast Neoplasms · United States, Taiwan | 2 | Withdrawn | Jan 18, 2029 | 0 |
| NCT04924101Small Cell Lung Carcinoma · United States, Austria, Canada and more | 2 | Completed | Jun 23, 2025 | 122 |
| NCT04165096Carcinoma, Non-Small-Cell Lung · United States, Hungary, Israel and more | 2 | Completed | Apr 30, 2025 | 128 |
| NCT04165070Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more | 2 | Recruiting | Feb 13, 2032 | 450 |
| NCT03396445Carcinoma, Non-Small-Cell Lung · United States, Chile, Israel and more | 1 | Completed | Sep 27, 2024 | 182 |
How it is read
Names in the registry
- “Boserolimab”, 5 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Small Cell Lung Carcinoma, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.